f10q_050813.htm
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
[x]
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2013
|
|
TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from _________ to _________
Commission File Number: 1-10526
UNITED-GUARDIAN, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware |
|
11-1719724 |
| (State or Other Jurisdiction of |
|
(I.R.S. Employer Identification No.) |
| Incorporation or Organization) |
|
|
230 Marcus Boulevard, Hauppauge, New York 11788
(Address of Principal Executive Offices)
(631) 273-0900
(Registrant’s Telephone Number)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes [x] No [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [x] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
| |
Large accelerated filer
|
[ ]
|
| |
Non-accelerated filer
|
[ ] (Do not check if a smaller reporting company)
|
| |
Smaller reporting company
|
[x]
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)
Yes [ ] No [x]
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:
4,596,439 shares of common stock, par value $.10 per share
(as of May 1, 2013)
UNITED-GUARDIAN, INC.
INDEX TO FINANCIAL STATEMENTS
Page No.
Part I. FINANCIAL INFORMATION
ITEM 1. Condensed Financial Statements
STATEMENTS OF INCOME
(UNAUDITED)
| |
|
THREE MONTHS ENDED
MARCH 31,
|
|
| |
|
2013
|
|
|
2012
|
|
| |
|
|
|
|
|
|
|
Net sales
|
|
$ |
3,952,161 |
|
|
$ |
3,888,692 |
|
| |
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
1,411,156 |
|
|
|
1,539,840 |
|
|
Operating expenses
|
|
|
561,568 |
|
|
|
602,863 |
|
|
Total costs and expenses
|
|
|
1,972,724 |
|
|
|
2,142,703 |
|
|
Income from operations
|
|
|
1,979,437 |
|
|
|
1,745,989 |
|
| |
|
|
|
|
|
|
|
|
|
Other income:
|
|
|
|
|
|
|
|
|
|
Investment income
|
|
|
54,182 |
|
|
|
69,591 |
|
|
Gain on sale of asset
|
|
|
--- |
|
|
|
2,750 |
|
|
Income from damage settlement
|
|
|
292,830 |
|
|
|
--- |
|
|
Total other income
|
|
|
347,012 |
|
|
|
72,341 |
|
| |
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
2,326,449 |
|
|
|
1,818,330 |
|
| |
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
761,800 |
|
|
|
589,700 |
|
| |
|
|
|
|
|
|
|
|
|
Net income
|
|
$ |
1,564,649 |
|
|
$ |
1,228,630 |
|
|
|
|
|
|
|
|
|
|
|
Earnings per common share (Basic and Diluted)
|
|
$ |
0.34 |
|
|
$ |
0.27 |
|
| |
|
|
|
|
|
|
|
|
|
Weighted average shares – basic and diluted
|
|
|
4,596,439 |
|
|
|
4,596,439 |
|
See notes to condensed financial statements
STATEMENTS OF COMPREHENSIVE INCOME
| |
|
THREE MONTHS ENDED
MARCH 31,
|
|
|
|
|
2013
|
|
|
2012
|
|
| |
|
|
|
|
|
|
|
Net income
|
|
$ |
1,564,649 |
|
|
$ |
1,228,630 |
|
| |
|
|
|
|
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Unrealized gain on marketable securities during period
|
|
|
25,712 |
|
|
|
95,171 |
|
| |
|
|
|
|
|
|
|
|
|
Income tax expense related to other comprehensive income
|
|
|
9,032 |
|
|
|
32,987 |
|
|
Other comprehensive income, net of tax
|
|
|
16,680 |
|
|
|
62,184 |
|
| |
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$ |
1,581,329 |
|
|
$ |
1,290,814 |
|
See notes to condensed financial statements
BALANCE SHEETS
|
ASSETS
|
|
MARCH 31,
|
|
|
DECEMBER 31,
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
2,029,112 |
|
|
$ |
1,748,382 |
|
|
Marketable securities
|
|
|
9,528,489 |
|
|
|
7,743,946 |
|
|
Accounts receivable, net of allowance for doubtful accounts of $29,000 at March 31, 2013 and December 31, 2012
|
|
|
1,993,514 |
|
|
|
1,017,627 |
|
|
Receivable in connection with damage settlement
|
|
|
97,610 |
|
|
|
518,050 |
|
|
Inventories (net)
|
|
|
1,058,004 |
|
|
|
1,242,750 |
|
|
Prepaid expenses and other current assets
|
|
|
167,786 |
|
|
|
132,458 |
|
|
Prepaid income taxes
|
|
|
--- |
|
|
|
3,602 |
|
|
Deferred income taxes
|
|
|
216,588 |
|
|
|
216,588 |
|
|
Total current assets
|
|
|
15,091,103 |
|
|
|
12,623,403 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Property, plant and equipment:
|
|
|
|
|
|
|
|
|
|
Land
|
|
|
69,000 |
|
|
|
69,000 |
|
|
Factory equipment and fixtures
|
|
|
3,863,287 |
|
|
|
3,842,927 |
|
|
Building and improvements
|
|
|
2,730,413 |
|
|
|
2,725,993 |
|
|
Waste disposal plant
|
|
|
133,532 |
|
|
|
133,532 |
|
|
Total property, plant and equipment
|
|
|
6,796,232 |
|
|
|
6,771,452 |
|
|
Less: Accumulated depreciation
|
|
|
5,583,338 |
|
|
|
5,535,589 |
|
|
Total property, plant and equipment, net
|
|
|
1,212,894 |
|
|
|
1,235,863 |
|
| |
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$ |
16,303,997 |
|
|
$ |
13,859,266 |
|
See notes to condensed financial statements
UNITED-GUARDIAN, INC.
BALANCE SHEETS
(continued)
LIABILITIES AND STOCKHOLDERS’ EQUITY
| |
|
2013
|
|
|
2012
|
|
|
Current liabilities:
|
|
(UNAUDITED)
|
|
|
(AUDITED)
|
|
|
Accounts payable
|
|
$ |
141,842 |
|
|
$ |
151,385 |
|
|
Accrued expenses
|
|
|
787,312 |
|
|
|
676,123 |
|
|
Income taxes payable
|
|
|
752,724 |
|
|
|
--- |
|
|
Total current liabilities
|
|
|
1,681,878 |
|
|
|
827,508 |
|
| |
|
|
|
|
|
|
|
|
|
Deferred income taxes
|
|
|
202,772 |
|
|
|
193,740 |
|
| |
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
Common stock $.10 par value, authorized, 10,000,000 shares; 4,596,439 shares issued and outstanding at March 31, 2013 and December 31, 2012.
|
|
|
459,644 |
|
|
|
459,644 |
|
|
Accumulated other comprehensive income
|
|
|
195,659 |
|
|
|
178,979 |
|
|
Retained earnings
|
|
|
13,764,044 |
|
|
|
12,199,395 |
|
|
Total stockholders’ equity
|
|
|
14,419,347 |
|
|
|
12,838,018 |
|
| |
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
$ |
16,303,997 |
|
|
$ |
13,859,266 |
|
See notes to condensed financial statements
STATEMENTS OF CASH FLOWS
(UNAUDITED)
| |
|
MARCH 31,
|
|
| |
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
Net income
|
|
$ |
1,564,649 |
|
|
$ |
1,228,630 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
47,749 |
|
|
|
66,943 |
|
|
Realized (gain) loss on sale of investments
|
|
|
(452 |
) |
|
|
6,489 |
|
|
Realized (gain) on sale of asset
|
|
|
--- |
|
|
|
(2,750 |
) |
|
(Decrease) increase in cash resulting from changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(975,887 |
) |
|
|
124,047 |
|
|
Receivable from damage settlement
|
|
|
420,440 |
|
|
|
--- |
|
|
Inventories
|
|
|
184,746 |
|
|
|
210,859 |
|
|
Prepaid expenses and other current assets
|
|
|
(35,328 |
) |
|
|
(4,224 |
) |
|
Prepaid income taxes
|
|
|
3,602 |
|
|
|
--- |
|
|
Accounts payable
|
|
|
(9,544 |
) |
|
|
(272,883 |
) |
|
Accrued expenses and taxes payable
|
|
|
863,913 |
|
|
|
697,325 |
|
| |
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
2,063,888 |
|
|
|
2,054,436 |
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
Acquisition of property, plant and equipment
|
|
|
(24,780 |
) |
|
|
(66,870 |
) |
|
Proceeds from sales of assets
|
|
|
--- |
|
|
|
2,750 |
|
|
Proceeds from sale of marketable securities
|
|
|
26,629 |
|
|
|
80,744 |
|
|
Purchase of marketable securities
|
|
|
(1,785,007 |
) |
|
|
(1,579,846 |
) |
|
Net cash used in investing activities
|
|
|
(1,783,158 |
) |
|
|
(1,563,222 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents
|
|
|
280,730 |
|
|
|
491,214 |
|
|
Cash and cash equivalents at beginning of period
|
|
|
1,748,382 |
|
|
|
1,090,974 |
|
|
Cash and cash equivalents at end of period
|
|
$ |
2,029,112 |
|
|
$ |
1,582,188 |
|
See notes to condensed financial statements
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients and other personal care products, pharmaceuticals, medical and health care products and proprietary specialty industrial products.
Interim financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation SX. In the opinion of management, all adjustments, consisting solely of normal recurring accruals, considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the current period are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2013. The interim unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2012.
|
3.
|
Stock-Based Compensation
|
The Company maintains a stock-based compensation plan for its employees and directors, which is more fully described in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company recognizes the fair value of all share-based payments to employees, including grants of employee stock options, as a compensation expense in the financial statements. As of March 31, 2013, the Company had no share-based awards outstanding and exercisable and did not grant any options during the three months ended March 31, 2013.
|
4.
|
Recent Accounting Pronouncements
|
In February 2013, FASB issued ASU 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income." This update requires the Company to report amounts being reclassified out of accumulated other comprehensive income by component. It also requires the Company to report either on the face of the financial statements or in the notes any significant amounts reclassified out of accumulated other comprehensive income, by the respective line items of net income, but only if the item reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For those amounts not required to be reclassified directly to net income in their entirety, the Company is required to cross-reference other disclosures that provide further details about the amounts. The amendments are effective for reporting periods beginning after December 15, 2012. The Company adopted this amendment effective January 1, 2013. The adoption of this amendment did not have a material impact on the Company's results of operations.
The fair values of the Company’s marketable securities are determined in accordance with GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by GAAP, which prioritizes the inputs used in measuring fair value, as follows:
|
·
|
Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
|
·
|
Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially for the full term of the financial statement.
|
|
·
|
Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.
|
The following available-for-sale securities, which comprise all the Company’s marketable securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs, which are quoted prices (unadjusted) for identical assets in active markets.
| March 31, 2013 |
|
|
|
|
|
|
|
|
|
| |
|
Cost |
|
|
Fair Value |
|
|
Unrealized
Gain (Loss)
|
|
|
Available for sale:
|
|
|
|
|
|
|
|
|
|
|
Corporate bonds (matures within 1 year)
|
|
$ |
203,920 |
|
|
$ |
203,060 |
|
|
$ |
(860 |
) |
|
Fixed income mutual funds
|
|
|
8,750,307 |
|
|
|
9,000,212 |
|
|
|
249,905 |
|
|
Equity and other mutual funds
|
|
|
274,631 |
|
|
|
325,217 |
|
|
|
50,586 |
|
| |
|
$ |
9,228,858 |
|
|
$ |
9,528,489 |
|
|
$ |
299,631 |
|
| December 31, 2012 |
|
|
|
|
|
|
|
|
|
| |
|
Cost |
|
|
Fair Value |
|
|
Unrealized
Gain (Loss)
|
|
|
Available for sale:
|
|
|
|
|
|
|
|
|
|
|
Corporate bonds (maturities of 1-5 years)
|
|
$ |
203,920 |
|
|
$ |
203,357 |
|
|
$ |
(563 |
) |
|
Fixed income mutual funds
|
|
|
6,991,181 |
|
|
|
7,242,998 |
|
|
|
251,817 |
|
|
Equity and other mutual funds
|
|
|
274,926 |
|
|
|
297,591 |
|
|
|
22,665 |
|
| |
|
$ |
7,470,027 |
|
|
$ |
7,743,946 |
|
|
$ |
273,919 |
|
Proceeds from the sale and redemption of marketable securities amounted to $26,629 for the first quarter of 2013, and generated realized gains of $452. Proceeds from the sale and redemption of marketable securities amounted to $80,744 for the first quarter of 2012, and generated realized losses of $6,489.
Investment income consisted principally of interest income from bonds and money market funds and dividend income from bond funds and mutual funds.
Marketable securities include investments in equity mutual funds, government securities and corporate bonds which are classified as “available-for-sale” securities and are reported at their fair values. Unrealized gains and losses on “available-for-sale” securities are reported as accumulated other comprehensive income (loss) in stockholders’ equity, net of the related tax effects. Investment income is recognized when earned. Realized gains and losses on sales of investments are determined on a specific identification basis.
| |
|
2013
|
|
|
2012
|
|
|
Inventories consist of the following:
|
|
|
|
|
|
|
|
Raw materials and work in process
|
|
$ |
499,994 |
|
|
$ |
481,544 |
|
|
Finished products
|
|
|
558,010 |
|
|
|
761,206 |
|
| |
|
$ |
1,058,004 |
|
|
$ |
1,242,750 |
|
Inventories are valued at the lower of cost or current market value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished products inventories at March 31, 2013 and December 31, 2012 are stated net of a reserve of $20,000 for slow moving and obsolete inventory.
|
7.
|
Supplemental Financial Statement Information
|
For purposes of the Statements of Cash Flows, the Company considers all highly liquid investments purchased with an initial maturity of three months or less to be cash equivalents.
For the first quarter of 2013 there was a cash payment for taxes in the amount $5,474, as compared with $9,245 in the first quarter of 2012. There were no payments for interest for the first quarters of 2013 and 2012.
Research and development expenses amounted to $148,300 and $146,342 for the first quarters of 2013 and 2012, respectively, and are included in operating expenses.
There were no dividends paid in the first quarters of 2013 and 2012.
The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. As of December 31, 2012 and March 31, 2013, the Company did not have any unrecognized tax benefits.
The Company files consolidated Federal income tax returns in the United States with its inactive subsidiary, and separate income tax returns in New York State. The Company is subject to examination by the Internal Revenue Service and by New York State for years 2009 through 2012.
The Company's policy is to recognize interest and penalties as interest expense.
Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities net of the related tax effect.
| Changes in Accumulated Other Comprehensive Income |
|
March 31, 2013
|
|
|
March 31, 2012
|
|
|
Beginning balance
|
|
$ |
178,979 |
|
|
$ |
34,612 |
|
|
Unrealized gain on marketable securities before reclassifications - net of tax
|
|
|
16,228 |
|
|
|
68,673 |
|
|
Realized gain/(loss) on sale of securities reclassified from accumulated other comprehensive income
|
|
|
452 |
|
|
|
(6,489 |
) |
|
Ending balance - net of tax
|
|
$ |
195,659 |
|
|
$ |
96,796 |
|
|
10.
|
Income From Damage Settlement
|
In May 2012 the Company’s supplier of RENACIDIN curtailed production due to manufacturing issues. As a result of that curtailment, the Company and its supplier entered into a settlement agreement whereby the supplier agreed to pay the Company $518,050 for profit the Company lost during 2012 as a result of the curtailment, and an additional $97,610 a month beginning January 1, 2013 for each month that the curtailment continues. The payments are to continue until either the supply contract ends in January 2014 or until production resumes, whichever occurs first. The Income from damage settlement of $292,830 in the first quarter of 2013 was paid to the Company by its RENACIDIN supplier pursuant to that settlement agreement.
|
11.
|
Defined Contribution Plan
|
The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions after one year of employment. The Company accrued $43,750 in contributions for each of the first quarters of 2013 and 2012. For the first quarters of 2013 and 2012 the Company did not make any discretionary contributions to the DC Plan.
|
12.
|
Related Party Transactions
|
During the three-month period ended March 31, 2013 the Company paid $2,000 to Bonamassa, Maietta and Cartelli, LLP for accounting and tax services. There were no payments made to that accounting firm in the first quarter of 2012. Lawrence Maietta, a partner in Bonamassa, Maietta and Cartelli, LLP, is a director of the Company.
Accrued Expenses
| |
|
March 31, 2013 |
|
|
December 31, 2012
|
|
| |
|
|
|
|
|
|
|
Accrued bonuses
|
|
$ |
343,500 |
|
|
$ |
229,000 |
|
|
Accrued distribution fees
|
|
|
175,155 |
|
|
|
196,617 |
|
|
Payroll and related expenses
|
|
|
114,412 |
|
|
|
72,306 |
|
|
Accrued annual report
|
|
|
42,060 |
|
|
|
66,000 |
|
|
Accrued audit fee
|
|
|
40,217 |
|
|
|
68,467 |
|
|
Other
|
|
|
71,968 |
|
|
|
43,733 |
|
|
Total Accrued Expenses
|
|
$ |
787,312 |
|
|
$ |
676,123 |
|
|
|
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
FORWARD-LOOKING STATEMENTS
Statements made in this Form 10-Q, which are not purely historical, are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified by the use of such words as "believes," "may," "will," "should," "intends," "plans," "estimates," or "anticipates" or other similar expressions.
Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices.
Accordingly, results actually achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
OVERVIEW
The Company is a Delaware corporation that conducts research, product development, manufacturing and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. All of the products that the Company manufactures, with the exception of its RENACIDIN® IRRIGATION (“RENACIDIN”), are produced at its facility in Hauppauge, New York, and are marketed through marketing partners, distributors, wholesalers, direct advertising, mailings, and trade exhibitions. Its most important personal care product line is its LUBRAJEL® line of water-based moisturizing and lubricating gels. It also sells two pharmaceutical products for urological uses. Those products are sold primarily through the major drug wholesalers, which in turn sell the products to pharmacies, hospitals, nursing homes and other long-term care facilities, and to government agencies, primarily the United States Department of Veterans Affairs.
The Company’s pharmaceutical products are distributed primarily in the United States. Its personal care products are marketed worldwide by five marketing partners, of which Ashland Specialty Ingredients ("ASI") purchases the largest volume of products from the Company. Approximately one-half of the Company's products are sold, either directly or through the Company’s marketing partners, to end users located outside of the United States. The Company’s non-pharmaceutical medical products (referred to hereinafter as “medical products”), such as its catheter lubricants, as well as its specialty industrial products, are sold directly by the Company to the end users or to contract manufacturers utilized by the end users, although they are available for sale on a non-exclusive basis by its marketing partners as well.
While the Company does have competition in the marketplace for some of its products, many of its products are either unique in their field or have some unique characteristics, and therefore are not in direct competition with the products of other pharmaceutical, specialty chemical, or health care companies. Many of the Company’s products are manufactured using patented or proprietary processes. The Company’s research and development department is actively working on the development of new products to expand the Company's line of personal care and performance products.
The Company recognizes revenue when products are shipped, title and risk of loss pass to the customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.
The Company has been issued many patents and trademarks and intends, whenever possible, to make efforts to obtain patents in connection with its product development program.
CRITICAL ACCOUNTING POLICIES
As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, inventory, patents, and income taxes. Since December 31, 2012, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.
The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2012, and a comparison of the results of operations for the three months ended March 31, 2013 and March 31, 2012. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations " included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
RESULTS OF OPERATIONS
Net sales for the first quarter of 2013 increased by $63,469 (1.6%) as compared with the first quarter of 2012. The change in net sales for the three-month period ended March 31, 2013 was primarily attributable to sales of the Company’s products, as discussed below.
|
(a)
|
Personal care products: For the first quarter of 2013 the Company’s gross sales of personal care products increased by $367,765 (14.1%) when compared with the same period in 2012. This increase was mainly due to an increase of $299,866 (13.4%) in sales to the Company's largest marketing partner for the first quarter of 2013 when compared with the same period in 2012. The Company believes that the overall increase in personal care product sales was due to a number of factors, including an increase in demand for the Company's products, the replenishment of low inventory levels of certain products by the Company’s largest marketing partner, and the timing of customer orders.
|
|
(b)
|
Pharmaceuticals: Gross sales of pharmaceuticals decreased by $570,698 (84.0%) in the first quarter of 2013 compared with the same period in 2012. The decrease was due to the absence of any sales of RENACIDIN in the first quarter of 2013, as compared with normal sales of that product in the first quarter of 2012. The Company has been unable to replenish its RENACIDIN inventory due to production issues encountered by the Company’s sole supplier. The Company’s inventory of RENACIDIN was depleted in July 2012, and there have been no sales of that product since that time. The Company’s supplier is paying the Company approximately $98,000 for each month that the product is not available, which the Company believes covers most of its lost profits each month. This will continue until either production resumes or the contract with the supplier ends on January 20, 2014, whichever comes first.
The Company is currently working with a new supplier that will manufacture the product in a new single-dose unit, which may increase the Company’s revenue from this product in future years. The Company is hopeful that production with the current supplier will resume before the contract ends, and that it will be able to bring in sufficient additional inventory to last until the new supplier is approved by the U.S. Food and Drug Administration, which the Company hopes will happen by the end of 2014.
|
|
(c)
|
Medical products: Gross sales of the Company’s medical products increased by $211,016 (32.1%) for the first quarter of 2013 when compared with the same period in 2012. The Company believes the increase was primarily due to the timing of customer orders.
|
|
(d)
|
Industrial and other products: Sales of the Company's specialty industrial products, as well as other miscellaneous products, increased by $21,255 (98.3%) for the first quarter of 2013 compared with the same period in 2012.
|
In addition to the above changes in sales, net sales allowances decreased by $34,132 (40.7%) for the first quarter of 2013 when compared with the same period in 2012. This decrease was primarily due to a decrease in chargebacks paid to the U.S. Department of Veterans Affairs, a reduction in pharmaceutical sales rebates to state Medicaid agencies, and lower distribution fees due to the lack of RENACIDIN sales.
Cost of Sales
Cost of sales as a percentage of sales decreased to 35.7% for the first quarter of 2013 from 39.6% for the first quarter in 2012. The decrease was primarily the result of the change in the Company's product mix due to the absence of RENACIDIN sales in 2013 and a proportionate increase in sales of the Company's higher-margin LUBRAJEL products.
Operating Expenses
Operating expenses consist of selling, general, and administrative expenses. Operating expenses decreased $41,295 (6.8%) for the first quarter of 2013 compared with the first quarter of 2012. This decrease was mainly due to a decrease in insurance costs.
Other Income
Other income increased by $274,671 (380%) for the first quarter 2013 compared with the first quarter of 2012. The increase was mainly attributable to $292,830 that was paid to the Company in the first quarter of 2013 by its RENACIDIN supplier in connection with the supplier’s curtailment of RENACIDIN production (see “Pharmaceuticals” above). The Company entered into an agreement with its RENACIDIN supplier whereby the supplier agreed to pay the Company $97,610 per month until either production resumes or the supply agreement ends on January 20, 2014, whichever comes first. Production is not expected to resume until the third quarter of 2013. For more information see the Company's Annual Report on Form 10-K for 2012.
The Company earns interest income from money market funds and bonds, and dividend income from both stock and bond mutual funds. The increase in Other income attributable to the RENACIDIN settlement in the first quarter of 2013 was partially offset by a decrease of $15,409 (22.1%) in investment income. This decrease was primarily due to the Company selling some of its marketable securities to pay for the December 2012 dividend paid by the Company. Other income was also lower by $2,750 in the first quarter of 2013 compared with the first quarter of 2012 due to a gain on sale of assets that took place in the first quarter of 2012 that did not recur in the first quarter of 2013.
Provision for Income Taxes
The provision for income taxes increased by $172,100 (29.2%) for the first quarter of 2013 when compared with the same period in 2012. This increase is mainly due to an increase in net income from operations before taxes of $508,119 (27.9%) in 2013 when compared with 2012.
The Company's effective income tax rate was approximately 33.0% for the first quarter of 2013 and 2012, and is expected to remain consistent for the current fiscal year.
LIQUIDITY AND CAPITAL RESOURCES
|
|
Working capital increased by $1,613,330 to $13,409,225 at March 31, 2013 from $11,795,895 at December 31, 2012. The increase in working capital is primarily due to an increase in marketable securities and accounts receivable, partially offset by an increase in taxes payable. The current ratio decreased to 9 to 1 at March 31, 2013 from 15 to 1 at December 31, 2012. The decrease in the current ratio was primarily due to the effect of an increase in income taxes payable.
|
During the three-month period ended March 31, 2013, the average period of time that an account receivable was outstanding was approximately 34 days. The average period of time that an account receivable was outstanding during the three-month period ended March 31, 2012 was 37 days. The decrease was mainly due to customers paying on a more timely basis.
The Company believes that its working capital is and will continue to be sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any significant capital expenditures for the remainder of 2013.
The Company generated cash from operations of $2,063,888 and $2,054,436 for the three months ended March 31, 2013 and March 31, 2012, respectively. The increase in cash was primarily due to decreases in the receivable from the RENACIDIN damage settlement and in inventory.
Cash used in investing activities for the three-month period ended March 31, 2013 was $1,783,158, while cash used in investing activities for the three-month period ending March 31, 2012 was $1,563,222. This increase was primarily due to an increase in the amount of marketable securities purchased in the first quarter of 2013 compared with the first quarter of 2012.
There was no cash used in financing activities for the first quarters of 2013 and 2012.
The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of other opportunities that are in the best interests of the Company, should they arise.
RECENT ACCOUNTING PRONOUNCEMENTS
Please see Note 4 to the Financial Statements for a description of recent accounting pronouncements, including the expected dates of adoption and the anticipated impact on the financial statements.
OFF-BALANCE-SHEET ARRANGEMENTS
The Company has no off-balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The information to be reported under this item is not required of smaller reporting companies.
|
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKETRISK.
|
The information to be reported under this item is not required of smaller reporting companies.
|
(a)
|
DISCLOSURE CONTROLS AND PROCEDURES
|
The Company’s management, including its Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Principal Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.
|
(b)
|
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
|
The Company's Principal Executive Officer and Principal Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.
|
|
PART II - OTHER INFORMATION
|
None
The information to be reported under this item is not required of smaller reporting companies.
|
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
|
None
|
|
DEFAULTS UPON SENIOR SECURITIES
|
None
None
None
| |
31.1
|
Certification of Kenneth H. Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
| |
|
|
| |
31.2
|
Certification of Robert S. Rubinger, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
| |
|
|
| |
32
|
Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
UNITED-GUARDIAN, INC.
|
| |
(Registrant)
|
| |
|
|
| |
|
|
| |
By: |
/S/ KENNETH H. GLOBUS |
| |
|
Kenneth H. Globus
President
|
| |
|
|
| |
|
|
| |
By: |
/S/ ROBERT S. RUBINGER
|
| |
|
Robert S. Rubinger
Chief Financial Officer
|
| Date: May 8, 2013 |
|
|
Page 17 or 17